Motif Neurotech

To-scale rendering of the prototype Motif DOT microstimulator used in first-in-human and large animal studies. [Image courtesy of Motif Neurotech]Motif Neurotech announced today that it brought in a Series A financing round worth proceeds of $18.75 million.

Arboretum Ventures led the financing with new investors KdT Ventures, Satori Neuro, Dolby Family Ventures and re.Mind Capital participating. Existing investors Divergent Capital, TMC Innovation, PsyMed Ventures, Empath Ventures and Capital Factory contributed as well.

The company also noted that Amy Kruse, chief investment officer of Satori Neuro, and Tom Shehab will join its board of directors.

Houston-based Motif Neurotech plans to use the funds to advance the development of its lead product, the DOT microstimulator. The company designed its miniature brain pacemaker to precisely stimulate the brain. It restores healthy circuit activity to treat mental health disorders. The pea-sized implant, which goe…

To-scale rendering of the prototype Motif DOT microstimulator used in first-in-human and large animal studies. [Image courtesy of Motif Neurotech]Motif Neurotech today announced new research highlighting the use of its millimeter-sized brain stimulator in a human subject.

Houston-based Motif Neurotech develops a miniature brain pacemaker designed to precisely stimulate the brain. It restores healthy circuit activity to treat mental health disorders. The pea-sized implant, which goes in during a 20-minute outpatient procedure, has capabilities for at-home therapy.

Motif Neurotech says it should produce minimal side effects compared to drugs. Its lead product treats treatment-resistant depression (TRD), a form of major depressive disorder (MDD).

The company conducted the study in collaboration with researchers at Rice University, Baylor College of Medicine and UTHealth Houston. The human procedure took place at Baylor St. Luke’s Medical Center.

I…